Laboratory studies demonstrate that the peptide was engineered as a fusion with HIV-TAT, a basic and hydrophilic sequence that enables energy-independent cellular uptake, ensuring effective intracellular delivery for precise molecular targeting in experimental settings
Typical research protocols structure dosing as follows: CJC-1295 administered subcutaneously at 12mg twice weekly, with MK-677 taken orally at 12.525mg once daily, preferably before sleep
Avoid foods high in saturated fats, added sugars, and refined carbohydrates like certain red meats, fried foods, sugary baked goods, candies, sodas, white bread, etc
From the founder, Sean Hall: I needed something that didn't exist yet, so I had to develop it myself